ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2020年06月23日 16時00分
Source:
Eisai
エーザイ、新株予約権証券の発行登録書の提出について
東京, 2020年06月23日 - (JCN Newswire) - 当社は、本日、「当社企業価値・株主共同の利益の確保に関する対応方針」(以下、本対応方針) に基づき、新株予約権証券の発行登録書を関東財務局に提出しました。本発行登録書の概要は下記の通りです。なお、本件は2019年6月21日に提出した発行登録書の期間(2019年7月1日から2020年6月30日)終了に対応するものです。
1.募集有価証券の種類:新株予約権証券
2.発行予定期間:発行登録の効力発生予定日から1年を経過する日まで(2020年7月1日から2021年6月30日)
3.募集方法:株主割当
4.発行予定額:8億円(上記は、新株予約権証券の発行価額の総額(無償)に新株予約権の行使に際して払い込むべき金額の合計額を合算した金額)
2020年6月19日に開催した取締役会において、社外取締役独立委員会より本対応方針を継続する旨の提案がなされ、審議の結果、提案通りに決議しました。本発行登録は機動的な株主割当による新株予約権発行を可能とするものです。
本対応方針の内容は、こちらをご参照ください。
(
https://www.eisai.co.jp/news/2020/pdf/news202028pdf.pdf
)
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2020/news202030.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
NTT and Olympus Demonstrate IOWN APN Low-latency Capability can be Used for Real-time Diagnosis and Treatment on Remote Server to Realize World's First Cloud Endoscopy System
Nov 19, 2024 19:10 JST
Kingsoft Announces 2024 Third Quarter Results
Nov 19, 2024 18:54 JST
Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings
Nov 19, 2024 09:02 JST
CleverTap Recognized as a Strong Performer in Cross-Channel Marketing Hubs, Q4 2024 Report
Nov 18, 2024 23:30 JST
World's First Successful Trial of Quantum Tokens Created Using Quantum Technology
Nov 18, 2024 17:29 JST
Fujitsu and SAP Fioneer enter partnership to accelerate digital transformation in the insurance industry and deliver services that contribute to customers' sustainable business
Nov 18, 2024 12:31 JST
Expanding Possibilities with the Liquid Hydrogen-Powered GR Corolla in the Season Final Round
Nov 18, 2024 09:25 JST
COP29: Indonesian Special Envoy Hashim Djojohadikusumo Announces EUR 1,2 Billion Green Funding
Nov 16, 2024 18:00 JST
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony of LNG-Powered Roll-on/Roll-off Ship TRANS HARMONY EMERALD in Shimonoseki
Nov 15, 2024 18:58 JST
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 17:33 JST
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 15, 2024 14:31 JST
Resorttrust Group and Mitsubishi Corporation Launch Joint Study in Medical Tourism
Nov 15, 2024 12:32 JST
Fujitsu collaborates with global suppliers in decarbonization initiative to exchange product-level primary data on CO2 emissions
Nov 15, 2024 10:13 JST
TANAKA Successfully Develops the World's First[1] Manufacturing Technology for Platinum Materials with Nano-Sized Crystal Grains
Nov 15, 2024 04:00 JST
myBillBook Leverages CleverTap to Elevate Customer Engagement and Drive Revenue Growth
Nov 14, 2024 20:00 JST
ULVAC Launches Oil Rotary Vacuum Pump Gv135
Nov 14, 2024 10:00 JST
MHI Publishes MHI REPORT 2024
Nov 13, 2024 16:52 JST
SoftBank Corp. and Fujitsu Strengthen Partnership for Realization of AI-RAN Commercialization
Nov 13, 2024 12:38 JST
Predictive Heart Monitoring Startup, GPx, Secures New Investment From NEC X; Joins Elev X! Boost Venture Studio Program
Nov 13, 2024 12:05 JST
NEC receives order for next-generation supercomputer system from Japan's National Institutes for Quantum Science and Technology and National Institute for Fusion Science
Nov 13, 2024 11:16 JST
More Latest Release >>
Related Release
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
11/15/2024 5:33:00 PM JST
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
11/15/2024 2:31:00 PM JST
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
11/5/2024 11:35:00 AM JST
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
11/1/2024 1:56:00 PM JST
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
10/31/2024 1:56:00 PM JST
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
10/31/2024 11:33:00 AM JST
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association
10/17/2024 8:01:00 PM JST
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia
10/17/2024 3:59:00 PM JST
Amyotrophic Lateral Sclerosis Treatment "Rozebalamin(R) for Injection 25 mg" Receives The Good Design Award 2024 for Light- Proof Vial Packaging
10/16/2024 7:14:00 PM JST
"Urece Tablets" (Dotinurad) Approved In Thailand For Gout And Hyperuricemia
10/8/2024 2:00:00 PM JST
More Press release >>